Screening

Latest News

Reduction in Cancer Screenings During COVID-19 May Lead to More Late-Stage Disease, Poorer Outcomes

November 29th 2021

Late-stage cancer and poor outcomes for patients may occur as a result of low screening numbers during the COVID-19 pandemic.

Clinical Limit of Detection May Represent Viable cfDNA Metric For Detection of Multiple Cancers

By Antonia DePace

September 19th 2021

An integrated review highlights the barriers standing between diverse LGBTQ populations and cancer screenings.

Overcoming Barriers to Cancer Screening in Diverse LGBTQ Populations

By Hayley Virgil

June 28th 2021

Decline in HPV-Related Cervical Cancer May Inform Screening and Vaccination Guidance for Other Tumor Types

By Audrey Sternberg

May 20th 2021

USPSTF Lowers the Recommended Age for CRC Screenings, Mandating Insurance Coverage

By Audrey Sternberg

May 18th 2021

Latest CME Events & Activities

Community Practice Connections™: Clinical Updates from Chicago – A Focus on What Community Centers Need to Know to Move Their Solid Tumors' Practices Forward

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations

Community Practice Connections™: Optimize the Diagnosis and Treatment of HER2-Positive Colorectal Cancer

Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease

Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition

December 6, 2024

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

Towards Personalized Treatment Approaches in Soft Tissue Sarcomas

22nd Annual Winter Lung Cancer Conference®

January 31, 2025 - February 2, 2025

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

42nd Annual Miami Breast Cancer Conference®

March 6 - 9, 2025

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

Exploring the Benefits and Risks of AI in Oncology

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

26th Annual International Lung Cancer Congress®

July 25-26, 2025

More News

Support for Minority Report on Mammography for Women in Their 40s

June 1st 2000

Weighing in unambiguously on the controversy over the National Institutes of Health (NIH) consensus statement on

Patients’ Reports of Counseling on Mammography Screening by Health Care Providers-North Carolina, 1997

August 1st 1999

Regular mammography screening combined with timely and appropriate treatment can reduce mortality from breast cancer by 30% in women ages 50 to 69 years and by 16% in women ages 40 to 49 years. A physician’s recommendation has

Some Medicare Managed Care Plans Restrict Mammograms

June 1st 1999

Some Medicare managed care organizations (MCOs) are telling beneficiaries that they need to get a referral from one of the plan physicians before they can get a mammogram. But that is not what the law says. A woman can get an annual, routine

Self-Reported Use of Mammography and Insurance Status Among US Women Over the Age of 39, From 1991 to 1992 and 1996 to 1997

December 1st 1998

In the United States, breast cancer is the most commonly diagnosed malignancy among women and the second leading cause of cancer death. Lack of health insurance coverage often is an important financial barrier to seeking preventive health care,

Accurate Mammogram Reading More Likely Following Mammotome Biopsy, Study Indicates

July 1st 1998

Mammotome biopsy causes significantly less internal breast scarring than open surgical biopsy and is less likely to interfere with a radiologist’s ability to read subsequent mammograms, according to a new study presented at the third annual

Self-Reported Use of Mammography Among Women ³ 40 Years Old

January 1st 1998

In 1997, breast cancer will be diagnosed in an estimated 180,200 women, and 43,900 women will die from the disease. Early detection combined with timely and appropriate treatment can alter the progress of and reduce mortality from this

AACR Comments on Mammography Screening for Women Age 40 to 49

March 1st 1997

The following position statement was made by the American Association for Cancer Research in response to the press release on mammography screening for women 40 to 49 years old issued by the National Institutes of Health

Swedish Study Supports Mammography Screening for Women Age 40 to 49

May 1st 1996

Areview of major clinical trials strongly supports the value of mammography screening for women in their 40s. The review showed a 24% decrease in deaths from breast cancer among women who underwent screening mammograms compared to

Should We Recommend Screening Mammography for Women Aged 40 to 49?

Laura J. Esserman, MD, MBA;Karla Kerlikowske, MD

March 1st 1996

In clinical trials, screening mammography has been shown to reduce mortality from breast cancer by about 25% to 30% among women aged 50 years and older after only 5 to 6 years from the initiation of screening. Among women 40 to 49 years old, the evidence supporting the efficacy of screening mammography is less convincing.

Economic Savings and Costs of Periodic Mammographic Screening in the Workplace

Robert I. Griffiths, MS, ScD;Margaret M. Mcgrath, MS;Victor G. Vogel, MD, MHS, FACP

March 1st 1996

his article discusses the costs and benefits of mammographic screening in the workplace. The cost of mammography itself and of diagnostic work-up are two of the largest costs involved.

Use of Mammography Services by Women Enrolled in Medicare--United States, 1991-1993

December 1st 1995

The incidence of invasive breast cancer among women age 65 years or older is twice that among those age 35 to 44 years,

Mammography Use--Wisconsin, 1980-1993

December 1st 1995

In the United States, efforts to reduce mortality from breast cancer focus primarily on secondary prevention (ie, early detection

<1 2